President Donald Trump on Friday brushed aside reports that he had signed off on a plan to remove Food and Drug Administration Commissioner Marty Makary, telling reporters outside the White House that he had no knowledge of the alleged move. The denial came hours after The Wall Street Journal reported that Trump had approved Makary's ouster following months of friction over flavored vaping products, abortion-pill policy, and the broader direction of federal health regulation.

Asked directly whether he planned to bring in a new FDA chief, Trump offered a flat "no, no," Fox News Digital reported. When pressed on what he knew about the reports, Trump said he had been "reading about it" but characterized the situation as "nothing much."

The exchange leaves Makary's future unresolved, and exposes a widening fault line inside the conservative coalition over who should run the agency that regulates everything from prescription drugs to baby formula.

How the friction started: vaping, pushback, and a presidential rebuke

The Wall Street Journal reported Tuesday that Trump had pressured Makary to fast-track approval for flavored nicotine vapes. Makary pushed back, and the resulting tension escalated quickly. By Friday, the Journal reported that Trump had signed off on a plan to fire his FDA commissioner, a claim the president then publicly downplayed within hours.

The Washington Examiner reported that Trump grew frustrated with the FDA's failure to move swiftly on approving new vaping products. That frustration, combined with broader dissatisfaction over Makary's management, turned the commissioner into what the Examiner described as a political and administrative liability for the White House.

The New York Post offered a sharper version of events. Trump was reportedly angry that Makary delayed implementation of FDA approvals for flavored e-cigarettes using age-verification technology. After being reprimanded, Makary reversed course, but the damage was done. "The president's over-the-weekend anger, followed by Makary's swift capitulation on Wednesday, uncorked an outpouring of attacks," the Post reported.

That reversal did not calm the waters. It widened them.

A coalition of critics, from pro-lifers to Big Pharma

Makary now faces pressure from nearly every direction. Pro-life activists accuse him of slow-walking a safety review for the abortion pill mifepristone. Pharmaceutical and biotech firms have opposed him over personnel cuts. And figures inside the administration have clashed with him on vaccine policy and FDA leadership decisions.

Marjorie Dannenfelser, president of SBA Pro-Life America, issued a statement calling for Makary's firing in stark terms:

"This is a five-alarm crisis for the pro-life movement and for the GOP. The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top."

That kind of language from a major pro-life organization carries real weight in Republican politics. It signals that Makary's troubles extend well beyond a policy disagreement over flavored vapes, and into the electoral math that shapes GOP strategy. Trump has previously shown willingness to remove top officials who generate sustained friction with his agenda or his base.

From the other side of the aisle, or at least from the biotech lobby, John Crowley, head of the Biotechnology Innovation Organization, condemned Makary's personnel decisions in a recent op-ed. Crowley wrote that "some of the administration's recent efforts to reform the federal government through aggressive and often indiscriminate personnel cuts have lacked the strategic insights necessary to modernize and reform our nation's health care agencies, especially the FDA."

When the pro-life movement and the pharmaceutical industry agree that the same person should go, the political ground beneath that person is thin.

MAHA allies rally to Makary's defense

Not everyone wants Makary out. Prominent voices aligned with the Make America Healthy Again movement, the health-reform wing associated with HHS Secretary Robert F. Kennedy Jr., have pushed back hard against the firing reports, framing them as an establishment campaign against a genuine reformer.

Kelly Ryerson, an author and popular advocate known as Glyphosate Girl, told Fox News Digital that Makary is an ally in the MAHA movement:

"It is not surprising that his uncaptured approach to protecting human health has been met with the swamp calling for his firing. The criticism is that he didn't approve flavored vapes quickly enough. The mothers who don't want their kids smoking find that reasoning alarming."

That framing, casting the firing push as a Big Pharma operation dressed up in policy language, found its loudest expression on social media. Alex Clark, a Turning Point USA-affiliated podcaster, wrote on X that the attacks on Makary are "coming from Big Pharma and the media outlets financially dependent on pharmaceutical advertising for survival." The broader pattern of Trump's willingness to publicly challenge powerful institutions makes the internal debate over Makary's future all the more significant.

Clark went further in a separate post, writing that "Washington SWAMP CREATURES hate Makary because he brings actual scientific scrutiny, independent thinking, and puts Americans' health FIRST." He urged Trump not to replace Makary "with a pharma puppet."

Vani Hari, a popular food blogger and prominent media figure in the MAHA movement, wrote that a Makary ouster "would be a horrible move."

A decision still in flux

Breitbart reported that while multiple major outlets cited anonymous administration sources saying Trump intends to fire Makary, the plan could still change if the president changes his mind. Neither HHS nor Makary publicly commented on the reports. Fox News Digital said it contacted the White House, HHS, the FDA, BIO, and SBA Pro-Life America for additional comment.

White House spokesman Kush Desai offered a general statement, as Newsmax reported: "President Trump has assembled the most experienced and talented administration in history, an administration that continues to focus on delivering more historic victories for the American people." The statement neither confirmed nor denied the firing reports.

Makary, a former oncology surgeon, was confirmed as FDA commissioner in March 2025. Since then, he has been involved in a series of controversies, from vaping approvals to abortion-pill reviews to personnel cuts that drew fire from both the biotech industry and health-policy advocates. The administration has also been active in directing FDA priorities on other fronts, including expedited drug reviews.

The New York Post noted that Trump has recently fired second-term agency leaders who brought him negative press, a pattern that increases the relevance of the pressure campaign against Makary. Whether this situation follows that pattern, or whether Trump's Friday denial signals a genuine reprieve, remains an open question.

The real stakes behind the FDA fight

Strip away the palace intrigue and the question is straightforward: Who should run the agency that approves the drugs Americans take, the food they eat, and the medical devices they rely on? The answer matters more than any single personnel dispute.

Makary's defenders say he is one of the few people inside the federal government willing to challenge pharmaceutical industry capture of the regulatory process. His critics, a coalition that spans the pro-life movement, the biotech lobby, and apparently some White House officials, say he has been too slow, too independent, or too resistant to presidential direction on key priorities. The administration's broader push to reshape the pharmaceutical landscape adds another layer to the stakes.

Both sides claim to be acting in the public interest. Both sides claim the other is captured by special interests. And the president, for now, says he knows "nothing about it."

In Washington, that phrase usually means the decision hasn't been made yet, not that it won't be. The people who actually live with the consequences of FDA policy deserve a commissioner chosen for competence, not as a concession to whichever lobby shouts the loudest.